SIRIO(SZ:300791)2022-08-25 16:00Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥1.11 billion, a decrease of 4.60% compared to ¥1.17 billion in the same period last year[22]. - The net profit attributable to shareholders decreased by 24.60% to approximately ¥109.92 million from ¥145.78 million year-on-year[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥96.31 million, down 27.72% from ¥133.24 million in the previous year[22]. - Basic earnings per share decreased by 24.69% to ¥0.61 from ¥0.81 in the previous year[22]. - The gross profit margin for the main business was 31.85%, down 2.83% year-on-year[76]. - The second quarter of 2022 showed improvement with a revenue increase of 4.97% and a net profit increase of 7.76% compared to the same period last year[38]. - The company reported a significant increase in revenue, achieving a year-on-year growth of 20% in the first half of 2022[149]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2022, representing a year-over-year growth of 25%[151]. Cash Flow and Assets - The net cash flow from operating activities increased by 35.29% to approximately ¥214.22 million, compared to ¥158.34 million in the same period last year[22]. - Total assets at the end of the reporting period were approximately ¥3.97 billion, an increase of 3.81% from ¥3.82 billion at the end of the previous year[22]. - The company's total assets included cash and cash equivalents of ¥745.94 million, accounting for 18.81% of total assets[79]. - The cash and cash equivalents decreased by 96.74% to ¥31.54 million, primarily due to the absence of funds raised from convertible bonds compared to the previous year[74]. - The company reported a cumulative investment income of CNY 15.93 million from financial products[88]. Research and Development - R&D investment for the first half of 2022 was CNY 39.621 million, a decrease of 1.91% year-on-year due to delays caused by the pandemic[40]. - The company emphasizes the introduction of high-end R&D talent and investment in R&D as a foundation for enhancing its product development capabilities[58]. - The company is investing in R&D, with a budget increase of 30% for new technology development[149]. - The company is investing heavily in R&D, with a budget allocation of 150 million for new technology development in 2022[151]. Market and Sales - Domestic sales revenue was CNY 673 million, a decline of 8.44%, while overseas sales revenue reached CNY 435 million, an increase of 1.89%[38]. - The company is focusing on organizational restructuring to enhance market insight and product innovation, aiming to maintain its competitive advantage[107]. - The company is accelerating its international strategy, aiming to become a leading player in the global nutrition and health food CDMO sector, with a focus on the U.S. market[44]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 10% market share in each[151]. Acquisitions and Investments - The company successfully reached an agreement to acquire 80% of Best Formulation Inc., a leading North American contract manufacturer, enhancing its production capacity and industry resources[45]. - The company approved the acquisition of 80% equity in Best Formulations Inc. during the board meeting on July 6, 2022[176]. - The company is considering strategic acquisitions to enhance its product portfolio, targeting a deal valued at approximately $100 million[149]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential mergers and acquisitions[151]. Risk Management - The company faces risks including COVID-19 pandemic risks, product quality management risks, and intensified market competition risks[6]. - The company has established an emergency response team to mitigate risks associated with the ongoing COVID-19 pandemic[103]. - The company is exposed to foreign exchange risks due to significant export activities, particularly in the Americas and Europe[108]. - The company employs strategies such as locking exchange rates with banks to manage foreign exchange risk effectively[108]. Corporate Governance and Shareholder Matters - The company did not distribute cash dividends or bonus shares for the first half of 2022[119]. - The participation rate of investors in the 2022 first extraordinary general meeting was 72.75%[117]. - The company plans to implement a stock incentive plan as part of its employee motivation strategy[120]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its initial public offering[147]. Social Responsibility and Sustainability - The company emphasizes sustainable development and environmental protection, implementing green office practices and reducing unnecessary travel[136]. - The company donated a total of 550,000 RMB in cash and materials to support pandemic prevention efforts in Hong Kong, including 200,000 RMB in cash and 20,000 masks[143]. - The company has invested in its own wastewater treatment facilities at each plant to ensure compliance with discharge standards[136]. - The company achieved a 100% signing rate of the social responsibility commitment letter among direct material suppliers during the reporting period[137].